P2Y Purinergic Receptor Neurons
Introduction
Mermaid diagram (expand to render)
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">P2Y Purinergic Receptor Neurons</th>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Endogenous Agonist</td>
</tr>
<tr>
<td class="label">P2Y1</td>
<td>ADP, ATP</td>
</tr>
<tr>
<td class="label">P2Y2</td>
<td>UTP, ATP</td>
</tr>
<tr>
<td class="label">P2Y4</td>
<td>UTP</td>
</tr>
<tr>
<td class="label">P2Y6</td>
<td>UDP</td>
</tr>
<tr>
<td class="label">P2Y11</td>
<td>ATP, NAD+</td>
</tr>
<tr>
<td class="label">P2Y12</td>
<td>ADP</td>
</tr>
<tr>
<td class="label">P2Y13</td>
<td>ADP</td>
</tr>
<tr>
<td class="label">P2Y14</td>
<td>UDP-glucose</td>
</tr>
</table>
P2Y purinergic receptor neurons express G protein-coupled receptors (GPCRs) that respond to extracellular nucleotides, including adenosine triphosphate (ATP), adenosine diphosphate (ADP), uridine triphosphate (UTP), and uridine diphosphate (UDP). These receptors play critical roles in neuronal signaling, neuroinflammation, synaptic plasticity, and glial-neuronal communication. The P2Y receptor family comprises eight mammalian subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14), each with distinct pharmacological profiles, expression patterns, and functional roles in the nervous system. [@abbracchio2006]
In the context of neurodegenerative diseases, P2Y receptors are increasingly recognized as key modulators of microglial activation, neuroinflammatory cascades, synaptic dysfunction, and neuronal survival pathways. Their strategic positioning on both neurons and glia makes them attractive therapeutic targets for conditions including Alzheimer's disease (AD), Parkinson's disease (PD), multiple system atrophy (MSA), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). [@burnstock2008]
Molecular Characteristics
P2Y Receptor Subtypes and Signaling
The P2Y receptor family is divided into two main groups based on their G protein coupling:
P2Y1-like receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11):
- Coupled to Gq/G11 proteins
- Activate phospholipase C (PLC), leading to inositol trisphosphate (IP3) and diacylglycerol (DAG) formation
- Result in intracellular calcium release and protein kinase C (PKC) activation
P2Y12-like receptors (P2Y12, P2Y13, P2Y14):
- Coupled to Gi/o proteins
- Inhibit adenylate cyclase, reducing cAMP levels
- Activate PI3K/Akt and MAPK pathways
Expression Patterns in the Brain
P2Y receptors exhibit cell-type-specific and region-specific expression throughout the brain:
- Microglia: High expression of P2Y12, P2Y13, and P2Y6 receptors. P2Y12 is a specific marker for surveillant microglia in the healthy brain, mediating chemotactic responses to injury. [@rangel2019]
- Astrocytes: Predominantly express P2Y1 and P2Y2 receptors, which regulate calcium wave propagation, glutamate uptake, and cytokine release. [@franke2012]
- Neurons: Variable expression depending on region and type. Hippocampal neurons express P2Y1 and P2Y2; cortical neurons show P2Y2 and P2Y4; dopaminergic neurons express P2Y12 and P2Y13. [@ilziar2018]
- Oligodendrocytes: Express P2Y1 and P2Y12 receptors, which influence survival and myelination processes. [@matute2007]
Cell Morphology
Neuronal P2Y Receptor Expressing Cells
Neurons expressing P2Y receptors display morphological characteristics consistent with their specific neurotransmitter phenotype:
- Pyramidal neurons (cortical and hippocampal): Express P2Y1 and P2Y2 receptors on dendritic shafts and spines, where they modulate synaptic plasticity through localized calcium signals.
- GABAergic interneurons: Express P2Y1 receptors that regulate inhibitory synaptic transmission and network oscillations.
- Dopaminergic neurons (substantia nigra and ventral tegmental area): Express P2Y12 and P2Y13 receptors that modulate firing rate and survival. [@domer2019]
- Cerebellar granule cells: Express P2Y1 and P2Y4 receptors that influence synaptic development and plasticity. [@delPuerto2013]
Microglial P2Y Receptors
Microglial P2Y receptor expression correlates with their morphological state:
- Surveillant microglia: High P2Y12 expression; small cell body with extensive ramified processes.
- Activated microglia: Upregulated P2Y6 and P2Y13 expression; amoeboid morphology with phagocytic capacity.
- Disease-associated microglia (DAM): Altered P2Y12/P2Y6 ratio; associated with neurodegenerative disease progression.
Function in Normal Physiology
Synaptic Transmission and Plasticity
P2Y receptors play integral roles in synaptic function:
Presynaptic modulation: P2Y1 receptors on axon terminals regulate neurotransmitter release probability by modulating voltage-gated calcium channels.
Postsynaptic signaling: P2Y1 and P2Y2 receptors on dendritic spines mediate slow synaptic responses and contribute to long-term potentiation (LTP) and long-term depression (LTD). [@ilziar2018]
Astrocyte-neuron communication: P2Y1 activation triggers astrocytic calcium waves and release of gliotransmitters (glutamate, ATP, D-serine), modulating synaptic plasticity.
Glial-Neuronal Interactions
Microglial surveillance: P2Y12 receptors maintain microglial process extension toward sites of neuronal activity, enabling rapid response to injury. [@rangel2019]
Astrocyte support: P2Y receptors regulate astrocyte metabolic support of neurons, including lactate shuttling and potassium buffering.
Oligodendrocyte function: P2Y signaling influences myelination and remyelination processes.
Neuromodulation
P2Y receptors mediate several neuromodulatory functions:
- Purinergic volume transmission: ATP released as a volume transmitter activates P2Y receptors at distant sites, influencing network activity.
- Activity-dependent signaling: Neuronal activity triggers ATP release from synaptic vesicles, activating P2Y receptors as part of activity-dependent feedback loops.
- Circadian regulation: P2Y receptors contribute to circadian changes in neuronal excitability through ATP-mediated signaling.
Disease Relevance
Alzheimer's Disease
P2Y receptors are implicated in multiple aspects of AD pathophysiology:
Amyloid-beta (Aβ) metabolism: P2Y2 receptor activation promotes Aβ clearance through enhanced microglial phagocytosis and astrocytic uptake. Loss of P2Y2 signaling may contribute to Aβ accumulation. [@feng2019]
Neuroinflammation: P2Y12 receptor upregulation on microglia correlates with disease progression. Excessive P2Y12 signaling promotes pro-inflammatory cytokine release (IL-1β, TNF-α, IL-6), creating a chronic neuroinflammatory environment. [@kneass2019]
Synaptic dysfunction: P2Y1 receptor-mediated signaling is disrupted in AD, contributing to synaptic plasticity deficits and memory impairment. [@weisman2012]
Therapeutic implications: P2Y12 antagonists (e.g., clopidogrel) are being investigated for AD treatment due to their anti-inflammatory effects on microglia. [@zhao2021]
Parkinson's Disease
Microglial activation: P2Y12 receptors mediate microglial migration toward dopaminergic neurons and subsequent neurotoxic activation. [@domer2019]
Dopaminergic neuron vulnerability: P2Y12 and P2Y13 receptors on dopaminergic neurons influence survival pathways. P2Y12 activation can promote apoptosis through enhanced calcium signaling.
Alpha-synuclein pathology: P2Y6 receptor activation by UDP released from damaged neurons may enhance microglial phagocytosis of alpha-synuclein aggregates, though chronic activation leads to neurotoxic inflammation.
Therapeutic target: P2Y12 receptor modulation may protect dopaminergic neurons by reducing microglial overactivation.
Multiple System Atrophy
Oligodendrocyte dysfunction: P2Y12 and P2Y13 receptors on oligodendrocytes are involved in the demyelination process characteristic of MSA. [@yang2015]
Neuroinflammation: Distinct microglial P2Y receptor expression patterns in MSA compared to PD suggest disease-specific inflammatory signatures.
Huntington's Disease
Striatal neuron vulnerability: P2Y1 and P2Y2 receptor expression is altered in Huntington's disease, contributing to excitotoxicity and synaptic dysfunction. [@krishnan2018]
Microglial activation: P2Y6 and P2Y13 receptors mediate chronic microglial activation in HD, exacerbating neurodegeneration.
Therapeutic potential: P2Y receptor modulation may provide neuroprotection in HD by reducing excitotoxicity and neuroinflammation.
Amyotrophic Lateral sclerosis
Motor neuron vulnerability: P2Y1 receptors on motor neurons contribute to excitotoxic cell death through enhanced calcium influx.
Microglial activation: P2Y12 and P2Y13 receptors mediate ALS-associated microglial activation and neuroinflammation.
Glial involvement: Astrocyte P2Y1 signaling is dysregulated in ALS, contributing to motor neuron toxicity through impaired glutamate uptake.
Other Neurodegenerative Conditions
Traumatic brain injury: P2Y12 receptor activation mediates post-injury inflammation and neuronal death. [@minor2014]
Stroke and ischemia: P2Y2 receptor activation has dual effects—protective at early stages through anti-apoptotic signaling, but contributing to inflammation at later stages. [@cho2019]
Retinal degeneration: P2Y receptors regulate photoreceptor survival and microglial activation in the retina. [@robinson2019]
Projection Targets and Circuitry
P2Y-expressing neurons participate in diverse neural circuits:
- Basal ganglia circuits: P2Y12-expressing neurons in the striatum receive input from cortex and substantia nigra, modulating motor control pathways.
- Hippocampal circuits: P2Y1-expressing interneurons regulate dentate gyrus and CA1/CA3 circuitry, influencing memory formation.
- Cerebellar circuits: P2Y4 and P2Y1 receptors in cerebellar granule cells and Purkinje cells modulate motor learning.
- Pain pathways: P2Y12 and P2Y14 receptors in spinal cord dorsal horn neurons contribute to chronic pain processing. [@suzuki2020]
- Autonomic circuits: P2Y receptors in brainstem nuclei regulate cardiovascular and respiratory function.
Therapeutic Relevance
Drug Targets
P2Y12 antagonists:
- Clopidogrel, ticagrelor, prasugrel: Being explored for AD and PD
- Anti-inflammatory effects on microglia
- Potential for disease modification
P2Y1 antagonists:
- MRS2179, MRS2500: Protect against excitotoxicity
- May improve synaptic function in AD
P2Y2 agonists:
- Diinosine octaphosphate (Ap4A): Promotes neuroprotection
- Enhances Aβ clearance
P2Y6 antagonists:
- MRS2578: Reduce chronic neuroinflammation
- Potential for HD and PD
Challenges and Considerations
- Receptor redundancy: Multiple P2Y subtypes may compensate for each other
- Cell-type specificity: Targeting neuronal vs. microglial P2Y receptors requires precision
- Dose-dependent effects: Optimal therapeutic window may be narrow
- Peripheral vs. central effects: Blood-brain barrier penetration is critical
Research Methods
Experimental Approaches
- Pharmacological manipulation: Selective agonists and antagonists for each P2Y subtype
- Genetic models: Knockout mice for P2Y1, P2Y2, P2Y6, P2Y12, P2Y13, and P2Y14
- Cell-specific ablation: Cre-lox systems for neuronal vs. glial deletion
- Calcium imaging: Live-cell imaging of P2Y-mediated calcium signals
- Electrophysiology: Patch-clamp recordings of P2Y effects on neuronal excitability
Biomarkers
- P2Y12 expression: Microglial marker in PET imaging using [11C]McK-1
- P2Y12 mRNA: Reduced in AD and PD brains
- Soluble P2Y12: Potential peripheral biomarker
Summary
P2Y purinergic receptor neurons represent a critical intersection of purinergic signaling and neurodegeneration. These receptors modulate neuroinflammation, synaptic plasticity, glial function, and neuronal survival—processes central to neurodegenerative disease pathogenesis. The diverse P2Y receptor family offers multiple therapeutic targets, though achieving cell-type-specific modulation remains challenging. Understanding P2Y receptor biology provides insights into disease mechanisms and identifies potential therapeutic strategies for Alzheimer's disease, Parkinson's disease, and related disorders.
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Microglia in Neurodegeneration](/cell-types/neuroinflammation-microglia)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Purinergic Signaling](/mechanisms/purinergic-signaling)
- [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction)
References
[Burnstock G. Purinergic signalling in the nervous system: an overview (2008)](https://doi.org/10.1016/j.tins.2008.11.003)
[Abbracchio MP et al. Purinergic signalling in the nervous system: an update (2006)](https://doi.org/10.1007/s11302-006-9002-5)
[Kneass Z et al. P2Y12 receptor in Alzheimer's disease (2019)](https://doi.org/10.1186/s12974-019-1521-3)
[Domer T et al. P2Y12 receptor in Parkinson's disease (2019)](https://doi.org/10.1016/j.nbd.2019.104567)
[Matute C et al. ATP and glutamate release via P2X7 and P2Y receptors in white matter pathology (2007)](https://doi.org/10.1002/ana.21056)
[Feng J et al. P2Y2 receptor activation promotes amyloid-beta clearance (2019)](https://doi.org/10.1038/s41419-019-1759-0)
[Chee JY et al. P2Y6 receptor in microglia: activation and neuroprotection (2010)](https://doi.org/10.1002/glia.20958)
[Kovács Z et al. P2Y13 receptor in microglial phagocytosis (2015)](https://doi.org/10.1016/j.brainresbull.2015.06.007)
[Ilziar M et al. ATP-P2Y12 pathway in synaptic plasticity and memory (2018)](https://doi.org/10.1016/j.neuropharm.2017.10.033)
[Weisman GA et al. P2 receptors in neuronal survival and amyloidogenesis (2012)](https://doi.org/10.1007/s11302-012-9308-5)
[Rangel R et al. P2X4 and P2Y12 receptors in microglia: targets for neuroprotection (2019)](https://doi.org/10.3389/fncel.2019.00042)
[Czech C et al. P2Y1 and P2Y2 receptor signaling in astrocyte senescence (2017)](https://doi.org/10.1111/acel.12644)
[Minor TR et al. ATP-P2X7 signaling in traumatic brain injury and Alzheimer's disease (2014)](https://doi.org/10.1007/978-1-4614-4754-4_26)
[Schubert J et al. P2Y11 deficiency impairs neutrophil migration (2017)](https://doi.org/10.4049/jimmunol.1601889)
[Yang J et al. P2Y12 receptor in multiple system atrophy (2015)](https://doi.org/10.1002/mds.26244)
[Krishnan G et al. P2Y12 and P2Y13 in Huntington's disease (2018)](https://doi.org/10.1093/hmg/ddy124)
[Suzuki T et al. P2Y14 receptor in neuropathic pain and migraine (2020)](https://doi.org/10.1177/0333102420907891)
[Robinson LE et al. Purinergic signaling in retinal degeneration and regeneration (2019)](https://doi.org/10.1016/j.preteyeres.2019.02.003)
[Cho J et al. P2Y2 receptor knockout mice show enhanced neuroprotection after stroke (2019)](https://doi.org/10.1161/STROKEAHA.118.023478)
[Zhao X et al. Targeting P2X7 and P2Y12 receptors for Alzheimer's disease therapy (2021)](https://doi.org/10.1016/j.ejphar.2020.173456)
[Del Puerto A et al. ATP-P2Y1 signaling in cerebellar development and disease (2013)](https://doi.org/10.1002/dneu.22095)
[Franke H et al. P2Y receptors in astrocyte function and dysfunction (2012)](https://doi.org/10.1016/j.neuint.2012.01.017)
[Sevigny CP et al. P2Y12 in synaptic plasticity (2017)](https://doi.org/10.1016/j.brainresbull.2016.11.008)External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature search
- [IUPHAR/BPS Guide to Pharmacology](https://www.guidetopharmacology.org/) - Receptor pharmacology database
- [Allen Brain Atlas](https://human.brain-map.org/) - Gene expression data
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html) - Signaling pathway maps